{"id":"https://genegraph.clinicalgenome.org/r/50636723-72b9-4688-9cb1-06c8d9bc02a9v1.2","type":"EvidenceStrengthAssertion","dc:description":"DOCK8 was first reported in relation to autosomal recessive hyper IgE syndrome by two groups in 2009 (PMIDs:19776401, 20004785). DOCK8 deficiency is associated with a combined immunodeficiency (CID) phenotype characterized by recurrent cutaneous infections, increased serum IgE levels, and severe atopic disease. Deficiency of DOCK8 is associated with defects in immune cell differentiation, migration, survival and activation. Heterogeneity of disease phenotype severity has been reported and is most likely due to germline variant reversion due to somatic repair (PMIDs:24797421, 33290277). These germline reversions of DOCK8 variants have been shown to reduce eosinophilia and atopy in patients, with rare patients being effectively cured of disease. However, only hematopoietic stem cell transplant has been shown to be curative in the majority of patients. Over 30 unique DOCK8 variants have been reported and are predominantly composed of frameshift, nonsense, splicing, indel variants along with large deletions. Evidence supporting this gene-disease relationship includes case-level and experimental data. Fifteen unique variants from 14 probands in 4 publications were curated (PMIDs:19776401, 20622910, 20004785, 33290277). More evidence is available in the literature, but the maximum score for genetic evidence has been reached (12 pts). Experimentally, in-vitro studies and animal models deficient for DOCK8 support this gene-disease relationship. DOCK8 null mouse models recapitulate defects of lymphocytes seen in patients (PMIDs:19898472, 22006977, 25422492), with in-vitro studies of patient cells showing abnormalities in DOCK8 protein expression and lymphocyte function, morphology and survival (PMID: 27554822, 25422492, 31021819). Somatic reversion of DOCK8 variants have shown to reduce disease phenotype severity and are correlative with the quantity of lymphocytes containing the reverted allele (PMIDs: 24797421, 33290277). In summary, DOCK8 is definitively associated with autosomal recessive hyper IgE syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. \nThis classification was approved by the ClinGen SCID-CID Working Group on DATE (SOP Version 8). \n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/50636723-72b9-4688-9cb1-06c8d9bc02a9","GCISnapshot":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2023-04-17T18:38:24.767Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10081","date":"2021-04-09T14:29:17.716Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e2954996-8aac-4089-bfdf-c4a13ca36396","type":"EvidenceLine","dc:description":"Expression of DOCK8 protein in primary T cells was evaluated in 2 patients, finding absent or severely reduced protein expression in these patients. Expression of DOCK8 protein was also measured in 7 other patients transformed T or B cells, demonstrating absent to trace expression of DOCK8 protein in all diseased patients, with all healthy controls and family members showing normal expression.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/994689ab-50a7-49fe-872f-52e7c84421cc","type":"Finding","dc:description":"Western blots for DOCK8 protein expression in family 1 and patient 2 of family 8 from primary T cell lysates.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","rdfs:label":"Western blot of patient cells or transformed cell lines","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/430b8503-184c-4da0-be8a-6d8e0e0ff966","type":"EvidenceLine","dc:description":"Show expression of DOCK8 in PBMCs in patients with AR-HIES and healthy controls","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/eeda1c55-d800-440a-8a2f-2829afcb2a10","type":"Finding","dc:description":"Flow cytometric analysis of DOCK8 protein expression in CD4 T cells, CD8 T cells and B cells show patients with bi-allelic variants of DOCK8 do not express DOCK8 protein","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31021819","rdfs:label":"DOCK8 expression in PBMCs of AR-HIES patients","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f6b31467-785a-452e-9669-a6c9600c9d6f","type":"EvidenceLine","dc:description":"This work by Tangye et al. demonstrates a CD4 T cell skewing towards TH2 differentiation and away from TH1 and TH17 differentiation. This alteration in CD4 T cell differentiation in DOCK8 deficiency helps to explain why these patients express more IgE and have more atopy, while being at high risk for fungal and viral disease.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/bf78b983-ed07-4977-83bb-ffcc805cd346","type":"FunctionalAlteration","dc:description":"Naive and memory CD4 T cells were isolated from healthy controls and DOCK8 null patient PBMCs and cultured for 5 days with TAE beads. Memory CD4 T cells from DOCK8 null patients displayed a cytokine production bias towards TH2 cytokine expression, with reductions in TH17 and TH1 cytokine expression.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/27554822","rdfs:label":"CD4 T cell cytokine skewing"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/dac73497-08fc-4bf3-8012-2655d1c6a0bd","type":"EvidenceLine","dc:description":"This work by Zhang postulates that the DOCK8 deficiency in skin homing lymphocytes leads to alterations in cytoskeletal regulation and the inability to support sustained resident memory T cells (TRM) in the skin, and may be why patients are more prone to viral skin infections. This inability for DOCK8 null T cells to migrate through collagen containing structures is correlated with increased herpes simplex virus skin infection and the inability to sustain TRM in DOCK8 KO mice. This work shows that DOCK8 null patient T cells have an elongated morphologic phenotype associated with worse survival in migration assays, and that this phenotype is also seen in mouse models. However, they do not show that this leads to reduced TRM in the patients, or that DOCK8 can reduce this morphology. Due to this, I have reduced the score to 0.5.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d1f07204-6bb7-4d1c-9189-237d457703d2","type":"FunctionalAlteration","dc:description":"Inability of DOCK8 null cells to maintain a normal shape and cellular organization while migrating in collagen gel matrices and human foreskin tissue. They show that migration of the patient cells leads to cytothripsis and cell death. This data is suggestive that DOCK8 deficiency leads to T cell death in vivo and inability to generate T resident memory cells that make patients more prone to viral skin infections.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25422492","rdfs:label":"Microscopy of patient cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/1153efab-dd20-4e5f-9c5f-e896aa4e8d78","type":"EvidenceLine","dc:description":"This manuscripts demonstrates that human cells deficient in DOCK8 are functionally skewed towards a TH2 phenotype. TH2 cells are associated with IgE production, atopy and hypersensitivity reactions when they are dysregulated. Thus, they are correlating the overproduction of TH2 associated cytokines with disease pathogenesis seen in DOCK8 deficiency.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b2757c19-5132-49f0-a04e-4f3819a19d46","type":"FunctionalAlteration","dc:description":"Increased production of type II cytokines by flow cytometry (IL-4 and IL-13)","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33020661","rdfs:label":"Th2 skewing of Dock8 deficient cells"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a04891b8-a730-475c-ac47-d33b5a7df115","type":"EvidenceLine","dc:description":"This work showed that DOCK8 gene reversion in a single allele resulted in improved clinical symptoms and improvement in T and B cell function. Functional studies compared lymphocytes that were DOCK8+ and DOCK8-, providing an internal control for each patient and subsequent experiments. This was seen in 3 patients, with 3 different variants. Due multiple examples of DOCK8 gene reversion improving clinical symptoms, I have awarded an extra point. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/818f58ba-3583-4bcb-9292-e745a4090c50","type":"Finding","dc:description":"These patients were identified because their symptoms and clinical score was improved with no identified changes in treatments. The comparisons in the functional studies were performed using DOCK8+ and DOCK8- lymphocytes, showing reversion of many of the reported phenotypes seen in the DOCK8- lymphocytes. Over time as more of the lymphoid compartment was derived from DOCK8+ lymphocytes, the patients clinical symptoms were reduced.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290277","rdfs:label":"Incidental reversion in 3 AR-HIES patients","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityHumanRescueCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/619e3c71-c64f-4a13-b958-e0fe32672ac6","type":"EvidenceLine","dc:description":"Using forward genetics this group identified 2 mice models of DOCK8 deficiency that led to poorly sustained antibody production and germinal center B cell maintenance. This phenotype is also seen in patients, with minimal antibodies produced against vaccines. However, there is no investigation of IgE, eosinophils, atopy or other characteristics of the human disease (-1.0).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/434a5ed9-3645-4a74-9ce1-7df4f9492a94","type":"Finding","dc:description":"Groups have shown absence of protective antibodies even though patients have been vaccinated. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19898472","rdfs:label":"DOCK8 forward genetics with 2 null variants","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5d7a73f3-94e7-4baf-9344-b49d89a55504","type":"EvidenceLine","dc:description":"This paper shows defects in the naive and memory CD8 T cell population along with poor proliferative response to stimuli in DOCK8 deficient patients. In the mouse model, they show similar loss of naive CD8 T cells as in humans, but do not replicate the same proliferative defect. However, they do show that  DOCK8 deficient CD8 T cell as are functionally unable to expand/accumulate after a secondary challenge in a heterosubtypic influenza model. This rechallenge model and phenotype is likely a better comparison to make to human patient data, but it is not further investigated. There is no analysis of IgE or eosinophilia that is typically seen in DOCK8 deficiency, so only part of the phenotype is replicated (-1).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25518a13-dbf3-4555-b29e-0a508cf140d1","type":"Finding","dc:description":"They show a similar reduction in naive T cells in mice and humans deficient in DOCK8. As well, the DOCK8 KO mice CD8 T cells do not respond well to secondary viral rechallenge, suggesting abnormalities in T cell memory and ability to control viral infections. Recurrent and/or diffuse viral infections are commonly seen in DOCK8 deficient patients, suggesting they also have poor memory CD8 T cell responses.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22006977","rdfs:label":"CD8 T cell impaired function in DOCK8 mouse KO model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"https://genegraph.clinicalgenome.org/r/07811d37-10c8-44dd-88b2-a2b574e59ac4_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e608d086-92c9-4af3-a2f9-378c0a3872dd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant is identified along with a deletion in Dock8 and an adjacent gene, so only this nonsense mutation is undergoing scoring. Western blot shows absence of Dock8 from this patient and their sibling (4-1 and 4-2 proband), demonstrating a null allele (Figure 3C). The mother of these probands was not typed, so it is unknown if this is a de novo mutation.","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0b4539cc-9ead-40cc-ae7d-4417aabcc637","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","rdfs:label":"4-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":17,"detectionMethod":"CGH followed by sanger. Also found a heterozygous mutation in Dock8 in father and sibling. However, it was not reported which mutation was identified as there were two identified in the proband. ","firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0033000","obo:HP_0001880","obo:HP_0032185","obo:HP_0001047","obo:HP_0000246","obo:HP_0002099","obo:HP_0410241","obo:HP_0005428","obo:HP_0000403","obo:HP_0410323","obo:HP_0012387","obo:HP_0011839"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e608d086-92c9-4af3-a2f9-378c0a3872dd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","allele":{"id":"https://genegraph.clinicalgenome.org/r/7706a443-18ba-4017-8bd3-070df7f777b7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.1357G>T (p.Glu453Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4957702"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/1f1fd154-82f0-41d9-aca3-3b2618954924_proband_score_evidence_line","type":"EvidenceLine","dc:description":"These DOCK8 variants in trans were found in germline samples from this patient with AR-HIES symptoms. These variants were not shown to be null variants, however, the patient has a subset of lymphocytes that were shown to have undergone DOCK8 reversion of the duplication event. These reverted lymphocytes were correlated with the DOCK8 protein expression, suggesting that these two variants in trans resulted in a null allele (+0.5).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a42ed5a-7ec0-47f3-87f7-63263d2b2e64","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290277","rdfs:label":"P2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":45,"detectionMethod":"WGS followed by sanger sequencing","firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0011108","obo:HP_0000403","obo:HP_0000988","obo:HP_0006532","obo:HP_0003765","obo:HP_0002110"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/1f1fd154-82f0-41d9-aca3-3b2618954924_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290277","allele":[{"id":"https://genegraph.clinicalgenome.org/r/d0fe633a-58a2-457a-b397-dc18a1cd1a84","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.5287C>T (p.Arg1763Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372768069"}},{"id":"https://genegraph.clinicalgenome.org/r/c25dc262-3e1c-42a1-a262-4fc4d17cbb5d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"A preferred title is not available","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CACN127897420"}}],"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/7bea754a-9d42-430f-994b-2337cde1b2fd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This individual was shown to have a homozygous large deletion within the DOCK8 gene (DOCK8 p.308S_922Ldel)(+1.5 and +0.75 for the second confirmed allele, round to 2pts). Both maternal and paternal samples were heterozygous for this variant. This variant was shown to result in an absence of DOCK8. Paternity and maternity were not verified, but due to the genotyping of parents, parenthood is most likely confirmed.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ec4d39d4-cba3-4a58-bfff-d52b65ad2be2","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","rdfs:label":"1-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"First performed CGH, followed by sanger sequencing of regions of interest","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Chromosomal microarray","phenotypeFreeText":"Poor CD8/PBMC cell expansion after CD3/CD28 stimulation (Figure 4A,B)\nLymphopenia, Elevated IgE levels, moderate eosinophilia","phenotypes":["obo:HP_0001047","obo:HP_0000348","obo:HP_0500093","obo:HP_0410295","obo:HP_0001888","obo:HP_0005353","obo:HP_0000670","obo:HP_0002090","obo:HP_0001880","obo:HP_0410338","obo:HP_0000403","obo:HP_0410241","obo:HP_0009098","obo:HP_0001510","obo:HP_0100658","obo:HP_0002209"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/7bea754a-9d42-430f-994b-2337cde1b2fd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","allele":{"id":"https://genegraph.clinicalgenome.org/r/bcac68b7-fc3c-4b78-afc1-f0e19f3788c5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"A preferred title is not available","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CACN82364174"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/75d50146-31ce-4a22-8b0c-41fed04a8e82_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This is a homozygous splice site mutation that leads to exon 25 skipping shown by cDNA sequencing and band size (evidence in figure 4c) (+1.5 and +0.75 for second allele rounded down to 2.0). No functional studies were performed in this study to demonstrate that this resulted in alterations in protein expression or function. Of interest, patients heterozygous for this mutation had no phenotype for HIES as reported by the authors.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/318fb06d-061d-4f39-a045-2c23f87b6010","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20004785","rdfs:label":"ARH010.8","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"detectionMethod":"All patients underwent homozygosity mapping using a SNP array. Following identification of homozygosity, patients underwent PCR and sanger sequencing. Some patients underwent DNA sequencing and/or PCR, while others with splice site mutations had cDNA made and analyzed using sager or gels.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0410324","obo:HP_0001880","obo:HP_0000964","obo:HP_0005353","obo:HP_0500094","obo:HP_0002788","obo:HP_0002090","obo:HP_0032336","obo:HP_0500093","obo:HP_0002728","obo:HP_0002099","obo:HP_0025615"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/75d50146-31ce-4a22-8b0c-41fed04a8e82_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20004785","allele":{"id":"https://genegraph.clinicalgenome.org/r/6600222e-a8f9-4499-b53c-7708a4d52cc0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.3120+1G>T (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372753155"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/cf01b3d1-5f34-4e02-a732-96d152c8ff76_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant identified here is in trans with a large deletion that extends beyond the DOCK8 coding sequence. Due to this large deletion, this patient is not scored.  Of interest, these variants were identified in a patient with AR-HIES symptoms. However, there was shown to be reversion of the 2bp deletion in a subset of DOCK8 expressing lymphocytes, while monocytes remained DOCK8 negative. Thus, these variants in trans lead to a loss of DOCK8 protein.","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/adb1713b-d594-4903-9d43-ee65b5f469ff","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290277","rdfs:label":"P3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":18,"detectionMethod":"WGS followed by sanger sequence to confirm","firstTestingMethod":"Whole genome shotgun sequencing","phenotypes":["obo:HP_0032163","obo:HP_0100649","obo:HP_0004313","obo:HP_0031292","obo:HP_0200043"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/cf01b3d1-5f34-4e02-a732-96d152c8ff76_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290277","allele":{"id":"https://genegraph.clinicalgenome.org/r/de538f68-0cb7-4b26-b977-e4bcb72b95d6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.5308_5309del (p.Leu1770HisfsTer14)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1120380100"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/87eddbd1-a848-426c-919e-91a738833465_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Two variants are identified by the paper (1.5+1.5). One is derived from the mother, while the other is either de novo or from the father (not specified). Western blot data shows a complete loss of DOCK8 protein, suggesting that the patient is null and that the two variant are in trans with each other. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d263e809-20d6-4ac5-91b9-507cf5ae1a42","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","rdfs:label":"7-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":13,"detectionMethod":"CGH followed by sanger sequencing","firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0025419","obo:HP_0030417","obo:HP_0003212","obo:HP_0012204","obo:HP_0001047","obo:HP_0410323","obo:HP_0006335","obo:HP_0100838","obo:HP_0001888","obo:HP_0006532","obo:HP_0000265","obo:HP_0001880","obo:HP_0001510","obo:HP_0500093","obo:HP_0005353","obo:HP_0012500","obo:HP_0410333","obo:HP_0410017"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/87eddbd1-a848-426c-919e-91a738833465_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","allele":[{"id":"https://genegraph.clinicalgenome.org/r/22aac6c1-9550-4303-94a6-7ffd7ce2d564","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.3494del (p.Thr1165LysfsTer29)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA10575596"}},{"id":"https://genegraph.clinicalgenome.org/r/78eb49df-7ee8-4e09-972d-4078b4a0d023","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.3500_3507dup (p.Ala1170TrpfsTer27)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA187767255"}}],"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/1a892013-5c0a-4883-9ec7-890f3db32e57_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant is found in an individual with another deletion in DOCK8 (chr9:278220_285346)_(chr9:395056_406292)del. This deletion is within the DOCK8 genomics coordinates and does not span into other genes. However, the exact genomic deletion coordinates are unknown. The presence of these 2 variants results in the absence of DOCK8 protein as shown by western blot (Figure 3C). The father of the patients expresses the DOCK8 c.742-15T>G variant, resulting in alternative splicing of the DOCK8 transcript (Figure S5B). Thus, I am only scoring 1 variant as the other variant deletion coordinates are unknown. However, this variant I am scoring does have functional proof (PCR showing splice site changes and western blot showing absence of protein expression).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/30d92a5b-6af6-4d15-97b7-9855f8f90e38","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","rdfs:label":"3-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":18,"detectionMethod":"CGH followed by conformation sanger sequencing\n\nFather was also sequenced with mutations found, no abnormalities found in mother","ethnicity":{"id":"cg:NotHispanicOrLatino"},"firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0002754","obo:HP_0000388","obo:HP_0005401","obo:HP_0002099","obo:HP_0031292","obo:HP_0410333","obo:HP_0032185","obo:HP_0410017","obo:HP_0410295","obo:HP_0020106","obo:HP_0001047","obo:HP_0005353","obo:HP_0001510","obo:HP_0011839","obo:HP_0003261","obo:HP_0030072","obo:HP_0005376","obo:HP_0033214","obo:HP_0410331","obo:HP_0012192","obo:HP_0410241","obo:HP_0005366","obo:HP_0030417"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/1a892013-5c0a-4883-9ec7-890f3db32e57_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","allele":{"id":"https://genegraph.clinicalgenome.org/r/8dad25a1-9d5a-44f6-884a-dac138b254c2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.742-15T>G","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/570541"}},"paternityMaternityConfirmed":"No"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3ce05245-2a1e-4c25-8657-9668d3960266_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant is shown to be homozygous and is found in both parents in the heterozygous state (consanguineous, +1.5 and +0.75 for second allele, rounded down to 2.0). This is predicted to result in the termination of DOCK8 at exon 7, however protein expression is not shown to confirm the null variant.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5e645fbd-b1d0-4d66-9937-ef0a4ccd860b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20004785","rdfs:label":"ARH012.3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":9,"detectionMethod":"SNP microarray for homozygosity mapping followed by sanger sequencing","firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0032185","obo:HP_0410241","obo:HP_0002099","obo:HP_0002090","obo:HP_0001880","obo:HP_0001287","obo:HP_0000964"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/3ce05245-2a1e-4c25-8657-9668d3960266_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20004785","allele":{"id":"https://genegraph.clinicalgenome.org/r/e75e176f-4026-4192-893d-5689249b6e92","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.811A>T (p.Lys271Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372761971"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/ddc0e940-fac2-4f76-8d27-2abe5f38bc84_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This patient was found to have 2 DOCK8 variants in trans in and was diagnosed with AR-HIES. However, she clinically improved and it was determined that one of her mutations reverted (splice site mutation), leading to partial expression of DOCK8 protein in a subset of PBMCs. In particular, her lymphocytes showed partial expression of DOCK8, while her monocytes were completely negative. Thus, these two variants lead to absent DOCK8 expression, and reversion of one variant will produce functional protein.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/755a4b3c-edbd-493f-b9d0-ca10681de074","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290277","rdfs:label":"P1","ageType":"AgeAtReport","ageValue":25,"detectionMethod":"Whole genome sequencing followed by sanger sequencing for confirmation. Long range PCR was also performed to confirm phasing of the variants","firstTestingMethod":"Whole genome shotgun sequencing","phenotypeFreeText":"Absent measles immunoglobulin after receiving the MMR vaccine","phenotypes":["obo:HP_0012203","obo:HP_0410241","obo:HP_0005428","obo:HP_0009098","obo:HP_0006532","obo:HP_0000403","obo:HP_0001047","obo:HP_0500093"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/ddc0e940-fac2-4f76-8d27-2abe5f38bc84_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33290277","allele":[{"id":"https://genegraph.clinicalgenome.org/r/05770abb-8cdd-430e-915c-bad31e35a92d","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.2206-2A>G (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA372763001"}},{"id":"https://genegraph.clinicalgenome.org/r/fae16c78-ab14-43ec-a883-2141a3469a49","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.850_851del (p.Leu284ValfsTer10)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4957491"}}],"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/6e20a27d-6e41-4a70-af3d-6d4bd82312f4_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant is found in a patient with another large deletion that spans beyond the DOCK8 gene. Thus, only this nonsense variant is scored for this proband (+1.5). This proband also has an affected sister(5-2) with the same mutations found as 5-1. However, neither parents were tested, so we are unable to determine if this variant is de novo or if they are in trans. Using western blot, they show an absence of DOCK8 protein expression with these two variants, supporting the conclusion that this variant along with the other complex deletion leads to a null variant, and is most likely in trans.","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f480eda8-b7bf-4fa3-bc06-2e991b390695","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","rdfs:label":"5-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":21,"detectionMethod":"CGH followed by sanger","firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0000218","obo:HP_0032445","obo:HP_0009098","obo:HP_0032170","obo:HP_0410151","obo:HP_0410295","obo:HP_0020102","obo:HP_0001888","obo:HP_0031292","obo:HP_0410338","obo:HP_0410323","obo:HP_0032185","obo:HP_0000246","obo:HP_0410303","obo:HP_0002099","obo:HP_0002110","obo:HP_0001047","obo:HP_0000403","obo:HP_0000265","obo:HP_0001880","obo:HP_0011113"],"secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/6e20a27d-6e41-4a70-af3d-6d4bd82312f4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","allele":{"id":"https://genegraph.clinicalgenome.org/r/49be5b0b-46bc-42ae-acb8-2db920c0d09b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.949C>T (p.Arg317Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA4957539"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/2f4513a7-182f-4ec9-a5f4-cb2e32cbd0d5_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This variant introduces a cryptic splice site, resulting in a 4bp deletion (found in cDNA sequencing, not in genomic sequencing) that results in a frameshift and introduction of a stop codon. This is predicted to result in the production of a truncated protein with the loss of a functional domain. A prior manuscript (PMID:19776401) showed the same family and this variant resulted in the significant loss of DOCK8 protein expression by western blot, but not a complete null variant (Figure 3C). Due to this variant not proven to be completely null, I am scoring it +0.5.","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/842ed3ea-d993-4ef2-86d5-52ea26842b4b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20004785","rdfs:label":"ARH011.3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":24,"detectionMethod":"Homozygosity mapping using SNP microarray followed by sanger sequencing","firstTestingMethod":"Homozygosity mapping","phenotypes":["obo:HP_0002090","obo:HP_0020114","obo:HP_0025615","obo:HP_0002754","obo:HP_0000964","obo:HP_0002788","obo:HP_0001880","obo:HP_0410241","obo:HP_0002728"],"previousTesting":true,"previousTestingDescription":"chromosomal microarray","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2f4513a7-182f-4ec9-a5f4-cb2e32cbd0d5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20004785","allele":{"id":"https://genegraph.clinicalgenome.org/r/8cfd2022-7406-4d18-af0a-aaade3dad87f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.1418A>G (p.Lys473Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA114673"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARNonNullCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/3e29312b-3354-4a83-9a2d-39ef75583e73_proband_score_evidence_line","type":"EvidenceLine","dc:description":"The c.742-18C>G (p.=) was shown to alter the splice site leading to an aberrantly spliced product in which exon 5 skips exon 6 and instead joins to exon 7, resulting in an out-of-frame premature termination (shown by PCR, figure S5). This variant was also found with a DOCK8 gene deletion (chr9:330142_346079)_(chr9:395056_406292)del. This deletion is within the DOCK8 coordinates and does not extend into other genes. However, the exact genomic coordinates are unknown. This combination of these 2 variants leads to absence of DOCK8 as demonstrated by western blot (Figure 3c). This variant is not located in the traditional +/-1,2 of the splice site, but since protein expression shows absence of DOCK8, I have upgraded the scoring to +1.5. Thus, even though they are not shown to be in trans, this variant is likely in trans with the deletion and is shown to lead to a null variant and a total loss of DOCK8 protein.  ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f90276ba-89a0-4085-a6c0-fd10837a0712","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","rdfs:label":"6-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":14,"detectionMethod":"Also used PCR to show splice site led to skipping of exon 6","firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0031392","obo:HP_0031292","obo:HP_0005406","obo:HP_0002650","obo:HP_0000246","obo:HP_0001880","obo:HP_0032336","obo:HP_0000218","obo:HP_0200043","obo:HP_0000403","obo:HP_0012395","obo:HP_0002110","obo:HP_0500093","obo:HP_0410295","obo:HP_0001047","obo:HP_0410303","obo:HP_0002754"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3e29312b-3354-4a83-9a2d-39ef75583e73_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19776401","allele":{"id":"https://genegraph.clinicalgenome.org/r/17c77ad2-fcad-4733-b3b3-b19daa45e1b4","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.742-18C>G (p.=)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA187809405"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/288d43ee-bcf8-4cba-bfa3-33d4842185be_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This patient was shown to have a compound heterozygous mutation in DOCK8. The first variant is a deletion in 9p deletion of at least 411,047 nucleotides encompassing the complete DOCK8 gene (chr9:176,581â€“587,627)del, and the second variant is included above. However, this deletion extends beyond the genomic coordinates for DOCK8 and is not included in scoring. Parents were not tested for this patient, so it is unknown if this is de novo. However, western blot of PBMC show absent DOCK8 protein, suggesting the variant results in the absence of DOCK8 protein expression (+0.5). ","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/dd213370-aa0d-4e17-9fab-ac54c0782283","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20622910","rdfs:label":"Patient 1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"Samples from patient underwent sequencing of DOCK8 exon as well as a SNP microarray to confirm copy number changes. ","firstTestingMethod":"Chromosomal microarray","phenotypes":["obo:HP_0006532","obo:HP_0000964","obo:HP_0006510","obo:HP_0005435","obo:HP_0032163","obo:HP_0011109","obo:HP_0001888","obo:HP_0001880","obo:HP_0004870","obo:HP_0032336"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/288d43ee-bcf8-4cba-bfa3-33d4842185be_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20622910","allele":{"id":"https://genegraph.clinicalgenome.org/r/801e4267-e26c-41a5-8b00-49e1b828fc97","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_203447.4(DOCK8):c.880_883del (p.Glu295GlyfsTer12)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1139655423"}},"paternityMaternityConfirmed":"none"}}],"specifiedBy":"GeneValidityProbandARDeNovoNullVariantCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":6151,"specifiedBy":"GeneValidityCriteria8","strengthScore":18,"subject":{"id":"https://genegraph.clinicalgenome.org/r/zXJLRkmUt6k","type":"GeneValidityProposition","disease":"obo:MONDO_0009478","gene":"hgnc:19191","modeOfInheritance":"obo:HP_0000007"},"version":"1.2","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_07811d37-10c8-44dd-88b2-a2b574e59ac4-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}